Digestive health

What GERD Actually Is

Save

Most explanations of GERD start with acid and stay there, which is why so many people picture a stomach producing too much of it. The acid is doing what acid does. What has failed is the valve keeping it downstairs. That single correction explains why GERD is diagnosed by pattern rather than by scan, why the drugs work the way they do, and why it is managed rather than cured.

Last updated: July 2026

Talk to a clinician

Gale can help you find a clinician in your state and request a visit.

Find care →

What separates GERD from ordinary heartburn?

A threshold, not a different substance. Reflux — stomach contents moving back up into the esophagus — happens to almost everyone occasionally, and in that ordinary form it has its own name: gastroesophageal reflux, or GER. It becomes gastroesophageal reflux disease when it turns persistent, when it produces troublesome symptoms, or when it starts causing complications 1.

GER is the event. GERD is the disease that event becomes once it crosses into persistent, symptomatic, or complication-causing territory 1.

This distinction does more work than it looks like it should. It means GERD is not a foreign process that healthy people never experience. It is a normal physiological event that has stopped being occasional and started being a problem — which is why the honest answer to how much heartburn is too much is a question about pattern rather than about any single bad night. One episode after an enormous meal is GER doing what GER does. The same burn several times a week, for months, waking you up, is the thing that has a name and a guideline attached to it.

It also means the boundary is partly clinical judgement rather than a bright line on a test result. Nobody measures a reflux count and reads a diagnosis off it. The definition is written in terms of persistence, trouble, and consequence 1 — three things a person reports, not three things a machine detects. That has real consequences for how the diagnosis gets made, which the sections below come to.

The mechanism is a valve, not an acid surplus

The causes NIDDK names are mechanical. A lower esophageal sphincter — the ring of muscle where the esophagus meets the stomach — that is weak or that relaxes when it should stay closed, and hiatal hernia, where part of the stomach pushes up through the diaphragm, are what allow stomach contents to travel the wrong way 2.

Notice what is not on that list: a stomach making too much acid. The acid in GERD is doing what acid normally does. The failure is in the door it is getting through.

This is the single most useful correction in the whole topic, because almost every downstream fact stops being arbitrary once it lands:

  • Why position matters. Lying flat takes gravity out of the equation. A valve that leaks a little is a valve that leaks considerably more when the contents above it are no longer being pulled downward. This is why reflux is so often a night-time complaint rather than a random one.
  • Why the medication does not fix the cause. Acid-suppressing drugs do not repair a sphincter. They change what comes through it, so what refluxes is less caustic and hurts less. The valve is untouched. This explains something that puzzles people badly: symptoms return when the drug stops, because the drug was never treating the mechanism in the first place.
  • Why surgery is a different category entirely. Operations for reflux address the anatomy rather than the secretion, which is why they sit at the far end of the treatment list and are reserved for cases that do not respond to what comes before 3.

The valve framing also dissolves a common and pointless guilt. Reflux gets interpreted as evidence of dietary failure — as something you brought on yourself with the wrong dinner. Food and posture influence how much the leak matters. The leak itself is structural. A person can eat with great care and still have a sphincter that does not hold.

What GERD actually feels like

Two symptoms define the classic picture, and NIDDK names both: heartburn and regurgitation 2. Heartburn is the burning behind the breastbone that people describe as climbing. Regurgitation is the sensation of stomach contents arriving back in the throat or mouth — sour, sometimes bitter, sometimes as actual fluid and sometimes only as a taste.

Regurgitation is the contents arriving. Heartburn is the esophagus reacting to them. Two halves of one event.

The word "heartburn" is a historical accident that causes real trouble. The pain sits behind the sternum because that is where the esophagus runs — directly behind the heart. The organ is a neighbour, not a participant. This anatomical coincidence is why reflux and cardiac pain get confused in both directions: people talk themselves out of cardiac pain by calling it heartburn, and people are frightened by heartburn that has nothing whatever to do with the heart. Chest pain is the one symptom where reflux is never a safe assumption to make at home, and the safety box below says what that means in practice.

A few features are worth knowing, because they are what a clinician is listening for:

  • Timing around meals, particularly large ones, and particularly on lying down afterwards.
  • A pattern rather than an event. Frequency and persistence are what the definition is built from 1, so a description covering weeks is more useful than a vivid account of one night.
  • Relief that is temporary and reproducible. Symptoms that reliably ease and reliably return describe a mechanism rather than a coincidence.

What is not on that list is severity. The pathways below key off pattern, response to treatment, and alarm features rather than off how much a given episode hurt 4 — which is worth knowing if you have been calibrating your worry to the intensity of the burn.

How GERD gets diagnosed, usually without a test

By pattern and by response, not by imaging. For classic heartburn or regurgitation without alarm features, the ACG recommends an eight-week empiric trial of a once-daily PPI 4. The treatment is the test. If the symptoms are what they appear to be, they respond; if they do not respond, that non-response is itself the finding that moves things forward.

This surprises people, who arrive expecting a scan and leave with a prescription, feeling unexamined. It is worth understanding why the pathway is built this way rather than experiencing it as a brush-off:

  • The diagnosis is defined by symptoms in the first place. Persistence, trouble, and complication are the definition 1. A test that does not measure those three things cannot confirm them.
  • The trial answers the question that matters. Whether acid suppression relieves the symptoms is simultaneously the practical question and the diagnostic one. The first step is designed to treat and inform at once 4.
  • The trial has an endpoint. Eight weeks is a defined course 4, not an open-ended prescription. Something is meant to happen at the end of it.

The ACG's empiric course for uncomplicated reflux is eight weeks 4.

That last point is where the pathway most often fails, and it fails in the follow-through rather than the design. The reassessment is the step that gets skipped. A trial with no closing conversation quietly becomes a long-term prescription that nobody actually chose, and the person taking it ends up years later trying to reconstruct why.

The pathway also has explicit exits. Alarm features and non-response both redirect toward endoscopy rather than toward more of the same 4. Both are covered further down.

The symptoms people do not connect to reflux

Reflux is sometimes suspected behind a chronic cough, hoarseness, or constant throat clearing rather than behind heartburn. These are the extraesophageal presentations, and the honest summary is that they are genuinely uncertain territory: the AGA's 2023 update states there is no single confirmatory test, that diagnosis rests on a global clinical impression, and that empiric PPI therapy is low-yield when typical GERD symptoms are absent 5.

Extraesophageal reflux means symptoms outside the esophagus itself — throat, larynx, airway — attributed to reflux.

That is a more careful statement than the topic usually gets, online or in person, where "silent reflux" is often presented as a confident diagnosis with a confident treatment. Two things follow from the AGA's framing.

First, the absence of a confirmatory test means nothing can come back negative. A hypothesis that cannot be disproven tends to persist indefinitely, which is a large part of how people end up on years of acid suppression for a cough that never clearly improved.

Second, "low-yield" is a statement about odds rather than an exclusion. Some people's cough genuinely is reflux. The AGA's point is narrower and more useful: when the classic symptoms are missing, an empiric trial is a weaker bet than it feels like 5. That is worth knowing before concluding that a failed trial means the reflux must be worse than anyone realised — the other available conclusion is that reflux was not the cause.

The practical upshot is a lower-confidence posture. Where typical heartburn and regurgitation sit alongside the cough, reflux is a reasonable suspect. Where they are entirely absent, it is a suspect that has not yet earned much.

What chronic reflux can do over years

The complication worth actually understanding is Barrett's esophagus. The ACG's guideline describes it as a complication of chronic GERD and the only known precursor to esophageal adenocarcinoma 6. That sentence deserves to be read at its true weight, which means neither waving it away nor inflating it — it routinely gets both treatments and rarely the accurate one.

Barrett's esophagus is a change in the lining of the lower esophagus, in which the normal cells are replaced by cells resembling those of the intestine, after prolonged acid exposure.

What "precursor" means, and what it does not:

  • It means the pathway runs through it. Barrett's is the known route to esophageal adenocarcinoma 6. That is why it is worth identifying at all.
  • It does not mean Barrett's becomes cancer. A precursor is a step that can be taken, not a step that is taken. The value of finding Barrett's is that it converts an unknown into something with a known pathway and a plan attached.

The ACG does not send everyone with reflux for a look. Its threshold for a single screening endoscopy is chronic GERD plus three or more risk factors 6 — a deliberately narrow gate, because scoping everyone with heartburn would be an enormous undertaking with a small yield. Where Barrett's is found, PPI therapy is part of the ACG's management 6, and barrett's surveillance then runs on its own intervals rather than on symptoms.

This is the practical reason it helps to be able to say how long your reflux has been going on. Chronic GERD is what that screening threshold is built on 6, and "a few years, maybe" is a weaker answer at an appointment than it needs to be. The duration is a fact about you that only you hold.

The treatment ladder

NIDDK groups the options into categories that ascend: lifestyle changes; over-the-counter and prescription medications — antacids, H2 blockers, and PPIs; and surgery for cases that do not respond 3. Reading them as a ladder rather than as a menu is what makes the shape make sense, because each rung is doing something different to the mechanism described above.

Lifestyle changes sit first because they act on the mechanics. Given a valve that leaks under pressure and without gravity's help, the interventions that plausibly matter are the ones that change pressure and gravity.

The medication tier contains three genuinely different things, which is why reflux medication types is a distinction worth having rather than a shelf to guess at. Antacids, H2 blockers, and PPIs 3 differ in how they work, how quickly, and for how long. They are not three strengths of one idea, and choosing between them is a real choice rather than a matter of picking the strongest.

Surgery is positioned for refractory cases 3 — reflux persisting despite the rungs beneath it. It addresses the anatomy rather than the acid, which is simultaneously its appeal and the reason it is not a first move.

This is also what makes the question is gerd permanent hard to answer cleanly. Every rung either manages the consequence or alters the anatomy. The categories NIDDK lists are treatments 3, and the condition NIDDK defines is a persistent one 1. GERD chronic management is the frame the guidance is written inside — an ongoing arrangement to be revisited, rather than a course to be completed and forgotten.

When reflux earns a scope

Two situations redirect from treatment to endoscopy, and the ACG names both: alarm symptoms, and failure to respond to the PPI trial 4. Barrett's risk is the third route in 46. Everything else — classic symptoms, responding to treatment, no alarm features — is deliberately managed without a look inside, and that is the pathway working rather than the pathway neglecting you.

A scope is not a reward for suffering enough. It is triggered by specific findings: alarm features, non-response, or Barrett's risk 4.

One technical detail matters and routinely gets missed. When endoscopy is done for a PPI non-responder, the ACG specifies that it be done off the PPI 4. Somebody who takes the drug up to the morning of the procedure may have changed what there was to see. This is worth raising when the appointment is booked rather than discovering it afterwards.

The GERD alarm symptoms are in the safety box below, and none of them is a fine judgement call: trouble swallowing, bleeding in either direction, unintended weight loss. They are listed because they change the timeline, not because they are likely. Most reflux is none of these things — and none of them is something to sit on merely because reflux is the commoner explanation. A common explanation being available is not a reason to skip looking for the uncommon one.

For the reader trying to place themselves: if your symptoms are classic and controlled, the pathway says you are where you ought to be. If they are classic and still not controlled after a proper trial, the pathway says the next step is a look rather than a stronger version of the same thing 4. Knowing when reflux needs a scope is mostly knowing which of those two sentences is describing you.

Common questions

No. Heartburn is a symptom; GERD is a disease defined by a threshold. Occasional reflux is called GER and happens to nearly everyone. It becomes GERD when it turns persistent, produces troublesome symptoms, or starts causing complications. Someone can have heartburn without GERD, and the difference is about pattern and consequence rather than about how much a given episode hurt.

Usually not. The causes NIDDK describes are mechanical: a lower esophageal sphincter that is weak or relaxes when it should stay shut, and hiatal hernia. The acid is behaving normally; it is arriving somewhere it does not belong. This is why acid-suppressing drugs change what refluxes rather than stopping the reflux, and why symptoms tend to return when they are stopped.

Usually no. For classic heartburn or regurgitation without alarm features, the ACG recommends an eight-week empiric PPI trial rather than a scope first. Endoscopy is directed at people with alarm symptoms, people whose symptoms do not respond to the trial, and people at risk of Barrett's esophagus. Being offered a prescription instead of a test is the pathway working as designed.

The guidance is written around management rather than cure. NIDDK's categories run from lifestyle change through medication to surgery for cases that do not respond, and the condition itself is defined as persistent. Surgery addresses the anatomy rather than the acid, which is why it sits at the far end. For most people GERD is an ongoing arrangement that gets revisited, not a course that finishes.

It is the informal name for extraesophageal reflux — cough, hoarseness, or throat clearing attributed to reflux without classic heartburn. The AGA is candid that there is no single confirmatory test, that diagnosis rests on overall clinical impression, and that an empiric PPI trial is low-yield when typical GERD symptoms are absent. It is a genuinely uncertain diagnosis, whatever the internet suggests.

Barrett's is a complication of chronic GERD and the only known precursor to esophageal adenocarcinoma, which is why it is taken seriously. A precursor is a step that can be taken, not one that is. The ACG's threshold for a single screening endoscopy is chronic GERD plus three or more risk factors — a narrow gate, because most people with heartburn do not meet it.

Related

Say it back

How would you explain this to someone you love?

Two or three sentences, just as you’d say it. Gale reflects back what you focused on — a mirror, not a quiz.

Talk to a clinician

Gale can help you find a clinician in your state and request a visit.

Find care →

The symptoms reflux does not explain away

  • —Chest pain with shortness of breath, sweating, nausea, or pain spreading to the arm, jaw, or back — the esophagus runs directly behind the heart, and reflux is never a safe assumption for new chest pain.
  • —Food that sticks or hangs up on the way down, swallowing that has become effortful, or pain on swallowing.
  • —Vomiting blood, or stools that are black and tarry — either can mean bleeding in the upper GI tract.
  • —Unintentional weight loss alongside reflux symptoms, without a change in diet or activity.

New or unexplained chest pain is a 911 call rather than a wait-and-see, particularly with shortness of breath, sweating, or pain radiating to the arm or jaw. Vomiting blood or passing black, tarry stools warrants an emergency department now.

This page explains what gastroenterology guidelines and NIDDK say about reflux disease. It is not medical advice and cannot tell you whether your symptoms are GERD. A burn behind the breastbone has more than one possible source, and only an evaluation that includes your history can sort them.

References

  1. 1.National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (2020). Definition & Facts for GER & GERD. NIDDK, National Institutes of Health. link ✓The definitional distinction between GER — occasional reflux of stomach contents into the esophagus — and GERD, which is persistent, symptomatic, or complication-causing reflux.
  2. 2.National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (2020). Symptoms & Causes of GER & GERD. NIDDK, National Institutes of Health. link ✓That the classic symptoms of GERD are heartburn and regurgitation, and that the causes described are mechanical — a weak or inappropriately relaxing lower esophageal sphincter, and hiatal hernia.
  3. 3.National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (2020). Treatment for GER & GERD. NIDDK, National Institutes of Health. link ✓The enumeration of GERD treatment categories: lifestyle changes, over-the-counter and prescription antacids, H2 blockers and PPIs, and surgery for refractory cases.
  4. 4.Katz PO, Dunbar KB, Schnoll-Sussman FH, Greer KB, Yadlapati R, Spechler SJ (2022). ACG Clinical Guideline for the Diagnosis and Management of Gastroesophageal Reflux Disease. American Journal of Gastroenterology. doi:10.14309/ajg.0000000000001538 ✓That the ACG recommends an 8-week empiric once-daily PPI trial for classic heartburn or regurgitation without alarm features, and that endoscopy — performed off PPI — is indicated for PPI non-responders, alarm symptoms, or Barrett's risk.
  5. 5.Chen JW, Vela MF, Peterson KA, Carlson DA (2023). AGA Clinical Practice Update on the Diagnosis and Management of Extraesophageal Gastroesophageal Reflux Disease: Expert Review. Clinical Gastroenterology and Hepatology. doi:10.1016/j.cgh.2023.01.040 ✓That for suspected extraesophageal reflux there is no single confirmatory test, diagnosis rests on global clinical impression, and empiric PPI therapy is low-yield when typical GERD symptoms are absent.
  6. 6.Shaheen NJ, Falk GW, Iyer PG, Souza RF, Yadlapati RH, Sauer BG, Wani S (2022). Diagnosis and Management of Barrett's Esophagus: An Updated ACG Guideline. American Journal of Gastroenterology. doi:10.14309/ajg.0000000000001680That Barrett's esophagus is a complication of chronic GERD and the only known precursor to esophageal adenocarcinoma, that the ACG recommends a single screening endoscopy for chronic GERD plus three or more risk factors, and that PPI therapy is recommended in patients with Barrett's.

6 sources, numbered by first appearance. General health information, not medical advice. AI-assisted editorial content — citations link their sources. Editorial policy

← Back to the health library